Bioequivalence Study of Gabapentin 400 mg Capsules Under Fed Conditions

Comparative, Randomized, Single-Dose, 2-Way Crossover Bioavailability Study of Ranbaxy and Parke-Davis (Neurontin®) 400 mg Gabapentin Capsules in Healthy Adult Volunteers Under Fed Conditions

To compare the single-dose oral bioavailability of metformin HCI liquid 500 mg/5 mL of Ranbaxy with Glucophage® 1000 mg tablets of Bristol-Myers, USA following administration of a 1000 mg dose in healthy, adult, male and female volunteers under fasting conditions

Study Overview

• Status: Completed
• Conditions: Healthy
• Intervention / Treatment: Drug: 400 mg Gabapentin Capsules

Detailed Description

This was an open-label, randomized, single-dose, 2-way crossover, relative bioavailability study performed on 24 healthy adult volunteers and 2 alternates. All 26 subjects completed the clinical phase of the study. In each period, subjects were housed from the evening before dosing until after the 36-hour blood draw. Single oral 400 mg doses were separated by a washout period of 7 days A total of 24 healthy adult volunteers and 2 alternates (17 males and 9 non-pregnant females) enrolled in and completed the clinical phase of the study

• Study Type: Interventional
• Enrollment (Actual): 24
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Canada
  • Quebec
    • Saint-Laurent,, Quebec, Canada
      • MDS Pharma Services

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 55 years (Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Healthy adult male or female volunteers, 18-55 years of age
2. Weighing at least 52 kg for males and 45 kg for females and within 15% of their ideal weights (Table of "Desirable Weights of Adults", Metropolitan Life Insurance Company, 1983)
3. Medically healthy subjects with clinically normal laboratory profiles

4. Females of childbearing potential should either be sexually inactive (abstinent) for 14 days prior to the study and throughout the study or be using one of the following acceptable birth control methods:

   • surgically sterile (bilateral tubal ligation, hysterectomy bilateral oophorectomy) 6 months minimum
   • IUD in place for at least 3 months
   • barrier methods (condom, diaphragm) with spermicide for at least 14 days prior to the start of the study and throughout the study
   • surgical sterilization of the partner (vasectomy for 6 months minimum)
   • hormonal contraceptives for at least 3 months prior to the start of the study

   Other birth control methods may be deemed acceptable. Postmenopausal women with amenorrhea for at least 2 years will be eligible.

5. Voluntarily consent to participate in the study.

Exclusion Criteria:

Subject candidates must not be enrolled in the study if they meet any of the following criteria:

1. History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease

2. In addition, history or presence of:

   • alcoholism or drug abuse within the past 2 years
   • hypersensitivity or idiosyncratic reaction to anticonvulsants
3. Female subjects who are pregnant or lactating
4. Subjects who have been on an abnormal diet (for whatever reason) during the 30 days prior to the first dose

5. Subjects who, through completion of the study, would have donated in excess of:

   • 500 mL of blood in 14 days, or
   • 500 - 750 mL of blood in 14 days (unless approved by the Principal Investigator)
   • 1000 mL of blood in 90 days
   • 1250 mL of blood in 12 days
   • 1500 mL of blood in 180 days
   • 2000 mL of blood in 270 days
   • 2500 mL of blood in I year
6. Subjects who have participated in another clinical trial within 28 days prior to the first dose

Study Plan

How is the study designed?

Design Details

• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: 1; 400 mg Gabapentin Capsules of Ranbaxy	Drug: 400 mg Gabapentin Capsules
Active Comparator: 2; Neurontin® 400 mg Gabapentin Capsules	Drug: 400 mg Gabapentin Capsules

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Bioequivalence

Collaborators and Investigators

• Sponsor: Ranbaxy Laboratories Limited

Publications and helpful links

Helpful Links

• Related Info
• Related Info
• Related Info

Study record dates

Study Major Dates

• Study Start: September 1, 2002
• Primary Completion (Actual): October 1, 2002
• Study Completion (Actual): December 1, 2002

Study Registration Dates

• First Submitted: October 22, 2008
• First Submitted That Met QC Criteria: October 22, 2008
• First Posted (Estimate): October 23, 2008

Study Record Updates

• Last Update Posted (Estimate): October 23, 2008
• Last Update Submitted That Met QC Criteria: October 22, 2008
• Last Verified: October 1, 2008

More Information

Terms related to this study

• Keywords: Bioequivalence gabapentin fed conditions
• Additional Relevant MeSH Terms: Pathologic Processes; Disease; Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Central Nervous System Depressants; Peripheral Nervous System Agents; Analgesics; Sensory System Agents; Excitatory Amino Acid Antagonists; Excitatory Amino Acid Agents; Tranquilizing Agents; Psychotropic Drugs; Anti-Anxiety Agents; Anticonvulsants; Antimanic Agents; Gabapentin
• Other Study ID Numbers: AA01820